NCT04598269View on ClinicalTrials.gov

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

April 8, 2021

Study Completion Date

April 22, 2021

Conditions
Atopic Dermatitis
Interventions
DRUG

ATI-1777

ATI-1777 topical solution 2.0% w/w

DRUG

Vehicle

Vehicle topical solution containing no ATI-1777

Trial Locations (14)

11415

Aclaris Investigational Site, Kew Gardens

19073

Aclaris Investigational Site, Newtown Square

23606

Aclaris Investigational Site, Newport News

24501

Aclaris Investigational Site, Lynchburg

29644

Aclaris Investigational Site, Fountain Inn

33613

Aclaris Investigational Site, Tampa

46250

Aclaris Investigational Site, Indianapolis

66215

Aclaris Investigational Site, Overland Park

68144

Aclaris Investigational Site, Omaha

78213

Aclaris Investigational Site, San Antonio

78759

Aclaris Investigational Site, Austin

85260

Aclaris Investigational Site, Scottsdale

90045

Aclaris Investigational Site, Los Angeles

91436

Aclaris Investigational Site, Encino

Sponsors
All Listed Sponsors
lead

Aclaris Therapeutics, Inc.

INDUSTRY